Iguratimod is an anti-inflammatory small molecule drug used for the treatment of rheumatoid arthritis, together with methotrexate in Japan and China. As of 2015 the biological target was not known, but it prevents NF-κB activation and subsequently selectively inhibits COX-2 and several inflammatory cytokines. Adverse effects include elevated transaminases, nausea, vomiting, stomach pain; rashes, and itchiness. During discovery and development it was called T-614 and it is marketed under the names Careram and Kolbet.